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The GENIUS-CHD Consortium 
 
A new global collaboration seeks to enhance our understanding of risk and improve secondary prevention 
among those with established coronary heart disease.  Bringing together 65 studies and more than a 
quarter of a million study participants, it is the most ambitious effort in this area to date.  
 
As a cardiology community we can take great satisfaction for improving outcomes from coronary heart disease 
(CHD). Public health measures and improvements in treatments have consistently reduced mortality from CHD 
in almost all high-income countries. However, this success has conversely led to a growing number of patients 
living with established and chronic CHD (3M in the UK; 16M in the USA), at high risk of subsequent fatal or 
non-fatal events such as myocardial infarction as well as complications such as heart failure and 
arrhythmia.  These often necessitate further hospitalization, revascularization and adjunctive, often costly, 
drug and device therapies. 
 
Despite the extent of this problem, relative to our understanding of risk for first CHD events, we know very 
little about determinants of subsequent CHD events, beyond those related to an acute index event (LV 
dysfunction, arrhythmia). Secondary prevention guidelines have remained largely unchanged for over a 
decade, and emphasize modification of the same lifestyle and risk factors as for primary prevention of 
CHD. This is based on the widely accepted but unproven assumption that first and subsequent CHD events 
have the same pathogenesis and therefore risk factors, obviating the need for separate study. 
 
Recent high profile failures of several new drugs have highlighted the problem of extrapolating observational 
findings from general populations to those with CHD (The negative Dal-Outcomes trial for example showed no 
post-hoc association between baseline HDL and outcomes, in contrast to the clear inverse relationship in 
general populations) – at enormous cost to both patients and industry.1  This is in line with observational 
studies often demonstrating paradoxical or inconsistent risk factor associations with outcomes in those with 
and without CHD.2-4  While lack of causality or bias may account for this, biological differences may also be at 
play, with recurrent event risk driven by, for example, unstable or vulnerable rather than stable plaques.  
These are known to differ in composition and prognosis and are likely to have different risk factor profiles.5  
Ultimately the high residual risk in apparently optimally treated patients highlights limitations of current 
management and indicates that there may be additional risk factors still to be identified and addressed.  
 
In 2013, we proposed that a greater understanding of determinants of subsequent events was urgently 
needed to enhance secondary prevention and drive effective drug development for this growing high risk 
population.  Importantly, this should be studied de-novo in patients with documented CHD rather than 
extrapolated from general populations.  In particular, we argued that genetic association studies would offer 
unique opportunities for identifying novel molecular mechanisms that predispose to subsequent event risk, 
such as plaque vulnerability pathways which may be amenable to drug therapy. 
 
In the absence of any single large resource for studying the genetic and non-genetic basis of CHD recurrence, 
we sought to bring together existing resources of patients with CHD at baseline, with prospective follow up 
and stored samples or completed genotyping.  Starting with our own cohorts and enthusiastic support from 
close collaborators, we formed a small grouping.  It was clear however that this was insufficient and so we 
identified more studies from literature searches, conference presentations and collaborator contacts and 
reached out to other PIs from across the globe, with an open and transparent invitation.  We were surprised at 
the unanimously positive responses from these groups who immediately shared our views and acknowledged 
the importance of the research and the need for close collaboration.   
 
Thus, GENIUS-CHD came into being (www.genius-chd.org).  The rather modest acronym stands for The 
GENetIcs of SUbSequent CHD. Today it consists of 65 prospective studies, with more than 250K consented 
participants with CHD at baseline and over 45K mortality events.  Studies include investigator led cohorts (e.g. 
angiographic or clinical CHD populations), randomized clinical trials (RCTs), or case–cohorts from larger 
population studies.  Most have stored samples (plasma, serum, DNA), genotype data as well as a rich and deep 
collection of phenotype data at scale (for example lipid profiles = 200K; ECG data = 120K; angiographic 
phenotyping = 140K).  The potential for cross-sectional studies as well as prospective studies on genetic and 
non-genetic exposures is clearly tremendous, and we anticipate such a global collaboration to be of significant 




The consortium is governed under a memorandum of understanding, which outlines the nature of the 
collaboration, governance structure and approach to analyses as well as details on publication policy and 
other matters.  The main scientific steering committee comprises the PI or a representative from each cohort 
and takes all key decisions including approving new proposals, while the operational committee oversees 
administrative and operational aspects of the consortium.  Project specific working groups (PSWGs) include 
those leading on an individual proposal and analyses.  Further details including participating studies and 
committee membership are available on our website at www.genius-chd.org.  
 
Important features of the consortium are that (1) participation is entirely voluntary as groups only participate 
in proposed analyses they feel are of value or they have the capacity to contribute to and (2) all data and 
samples belong to and remain with the PI and are not shared directly or stored centrally. This is possible 
because of a federated analysis approach, whereby a standardized script is generated by us or any persons 
leading an analysis, which is then shared (with detailed instructions using R) with all members who then run 
analyses locally.  The outputs with summary level data are shared with the central sites at UCL and UMC 
Utrecht for QC and meta-analysis.  For groups with limited statistical or staff capacity, the analytical team 
offers close support and also the option to run the analysis in its entirety using an anonymized dataset. 
 
Currently, the consortium has successfully run its first analysis using this framework, exploring genetic 
association between 3 candidate loci and subsequent event risk.  Data are being analyzed with a view to 
publication by the end of the year along with a formal design paper describing the consortium and its 
participants.  A pathway and process for new project applications has been developed and we hope to invite 
new project proposals in the near future, initially from consortium members and in time from external 
investigators. 
 
The scale and nature of the GENIUS-CHD consortium, also offers scope to tackle key challenges in CHD 
prognosis research.  Firstly, CHD is a heterogenous phenotype, often used to satisfy the need for statistical 
power.  With the sample size available, we anticipate disaggregating this into more strict CHD phenotypes 
including acute and stable CHD at baseline.  Additionally, further stratification on variables such as time of 
recruitment, country and health system, LV function among others will be possible.  Secondly, methodological 
questions around specific biases will also be addressed with advanced modelling and simulation studies.  A 
core group of statisticians from consortium member groups are currently working to develop ways of handling 
and estimating the impact of survival and index event biases on planned association studies.   
 
Despite the unprecedented size of the consortium, more cohorts are still needed, to satisfy the need to 
subgroup and disaggregate the CHD phenotypes without loss of power.  We invite and warmly welcome all PIs 
with (1) any collections of patients with CHD at baseline (investigator led cohorts, RCTs, nested cohorts) and 
(2) prospective follow up for events and (3) baseline samples/DNA or completed genotyping to join the 
consortium.  We are happy to consider all studies, even if the stated criteria are not fully met.  Membership 
benefits for individual groups include (a) greater publication opportunities and routes to impact (b) access to 
other similar cohorts for replication of local research (c) leveraging of greater funding opportunities (d) 
enrichment of member cohort datasets (including genotyping) through funding acquired for consortium 
projects. 
   
In summary, the GENIUS-CHD consortium is a global partnership of researchers seeking to better understand 
risk in those with CHD with a view to ultimately enhancing secondary prevention.  It seeks to be an open and 
transparent entity and invites all PIs with suitable cohorts to join and collectively enhance its efforts. 
  
For further information please contact Riyaz.patel@ucl.ac.uk or F.W.Asselbergs@umcutrecht.nl.  Please also 
refer to our website for further information www.genius-chd.org 
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Figure 1 – Overview of the GENIUS-CHD consortium; *Approximate numbers only at the time of survey 
 
 
